ArcherDX agrees to acquisition by genetics tester Invitae for up to $1.4B By Dan Mika — June 22, 2020 BOULDER and SAN FRANCISCO — Just weeks after it filed for a $100 million initial public offering, Boulder genomics testing company ArcherDX … Investors were convinced by the pitch: Invitae’s stock closed up 45%, adding more than $1bn to the company’s valuation. About Invitae Invitae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. It was only on June 5 that ArcherDX said in a Securities and Exchange Commission filing that it would seek to raise $100 million through an initial public offering. Learn more. CLICK HERE TO TURN ON NOTIFICATIONS. BOULDER and SAN FRANCISCO — Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for cancer patients into the San Francisco company’s fold. Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for cancer patients into the San Francisco company’s fold. The companies said that combining together would enable cancer patients to access germline and somatic testing, liquid biopsy and tissue genomic profiling through a single platform in order to test for risk, therapy optimization and personalized monitoring of their disease. In the meantime, it has formed partnerships with a variety of drug companies both to use its products in clinical trials and to develop companion diagnostics. Stock Alert: Invitae Stock Surges On Acquisition Of ArcherDX . These beautifully renovated apartments in... A lot of the pain we experience is caused by inflammation. ArcherDX had previously applied for an IPO before the public company its acquisition was announced. Greenwood & Myers Mortuary in Boulder are... You’re looking for an apartment in a great neighborhood. Get the latest industry news first when you subscribe to our daily newsletter. The DX is the green alternative, powered by the Continental CD-155 diesel engine, burning the more efficient jet fuel. “ArcherDX and Invitae share a foundational belief in the power of genomic information to impact care,” ArcherDX CEO Jason Myers said in a statement. Learn more with a new report from Omada Health. NEW YORK – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDx. Families who have lost a loved one often need help with funeral planning. ArcherDX’s platform specifically focused on cancers and the growing group of drugs that aim to turn off genetic markers thought to fuel cancer growth once mutated. Acquisition of antigens, antibodies, and blocking buffers producer expands Medix’s antibody and antigen offering in drugs of abuse, infectious disease and veterinary testing; OraSure Technologies: UrSure: Price: $3 million cash + up to $28 million in post-closing contingent payments; Status: No … Bristol-Myers Squibb markets two immuno-oncology drugs, namely the PD-1 checkpoint inhibitor Opdivo (nivolumab) and the CTLA4 inhibitor Yervoy (ipilimumab), while AstraZeneca markets the PD-L1 inhibitor Imfinzi (durvalumab). GET BREAKING NEWS IN YOUR BROWSER. ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. Piper continues to evolve to meet the modern pilot’s needs, while promoting the most fundamental legacy and maintaining the original intent: A passion for flying. Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. In a statement Monday, Invitae said it will pay $325 million in cash and up to 30 million shares to ArcherDX’s investors, along with 27 million additional shares linked to future milestones. In connection with the acquisition, Invitae sold $275.0 million of common stock to certain accredited investors in a private placement. What happened Shares of Invitae (NYSE:NVTA) rose as much as 48.4% today after the company announced the acquisition of ArcherDX. At a total transaction cost of … A new guide from Bright.MD offers a digital checklist on how to improve the patient experience. As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has never been more critical. Developer of next-generation sequencing-based gene fusion detection assays intended to target enrichment chemistry. ArcherDX originally planned to go public, filing for an initial public offering of $100 million in early June before abandoning that effort for the Invitae offer less than a month later. Lockdown has profoundly suppressed medtech dealmaking, but it has not annihilated it altogether. “With the addition of ArcherDX’s technologies, capabilities and team, Invitae is now well positioned to accelerate the utilization of genetic information throughout a cancer patient’s journey,” Invitae CEO Sean George said in a statement. … ArcherDX General Information Description. You can reach him at dmika@bizwest.com or on Twitter at @DanMikaTweets. RTTNews.com RTTNews Published. The company, started in 2013, developed a suite of tools to help clinicians with patient care and … BOULDER and SAN FRANCISCO — Just weeks after it filed for a $100 million initial public offering, Boulder genomics testing company ArcherDX Inc. is … Contributor. ArcherDX is also currently developing in-vitro diagnostic (IVD) products, including STRATAFIDE DX, for therapy optimization, an estimated $5 billion market opportunity with U.S. Food and Drug Administration (FDA) submissions planned this year, and the broadly applicable Personalized Cancer Monitoring (PCM) in development for disease recurrence monitoring, therapy optimization … This Patient Experience Checklist Is Your Key To Success in 2021, Vaccine rollout is an administrative problem, not a distribution issue and is expected to go away, MedCity INVEST Precision Medicine spotlight: Pitch Perfect Life Science track (video), Transforming the patient experience to enable informed healthcare decisions. “We are thrilled to unite with Invitae to form the leading hub for precision oncology, diagnostics, therapy optimization and monitoring, with an opportunity to accelerate both patient care and shareholder value.”. In an interview with BizWest at the time, Myers said ArcherDX’s technology will be easier for patients to access through Invitae’s distribution platform rather than through ArcherDX as a smaller standalone firm. In connection with the acquisition, Invitae entered into a credit agreement and guaranty with Perceptive Credit Opportunities Holdings III, LP providing for a senior secured term loan facility, and on October 2, 2020, borrowed an aggregate principal amount of $135.0 million under the credit agreement and guaranty. Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index. ArcherDX CEO Jason Myers will remain as the business head and will join Invitae’s board. Registration or use of this site constitutes acceptance of our Terms of Service and Privacy Policy. Report: ‘Pharmacy deserts’ may significantly hinder vaccine rollout, Boston Scientific to acquire cardiac monitoring company Preventice for $925M, Trump’s pardons included healthcare execs behind massive frauds, Why payers need top-notch digital data management, Amwell CEO: Telehealth’s future is in the relationship between clinicians and patients, Aneesh Chopra: It’s the people problem that remains at the core of cyberattacks, After $1.6B blank-check deal, Hims & Hers plots expansion into more conditions, Biden appoints permanent ONC head, acting CMS, HHS leaders, How AI is reshaping the future of the patient-provider experience, VC playing field tilts to established companies, funds, In the final days of Trump administration, agencies clashed over how to regulate medical AI, Telehealth, online pharmacy key focus for UnitedHealth, leaders say, Drug price hikes without new evidence upped spending by $1.2B, ICER says, Capital BlueCross provides members access to mental health app. Looking for quality landscaping services for your home or business? ArcherDX has a post-money valuation in the range of $100M to $500M as of Dec 17, 2019, according to PrivCo.Sign up for a free trial to view exact valuation and search companies with similar valuations. With 15% less acquisition costs*, the Archer DX offers a compelling argument in the current economy. COVID-19 pandemic has underscored the need for a healthcare system that can help patients easily navigate healthcare concerns as well as price transparency. San Francisco-based genetics company Invitae will put up about $1.4 billion to acquire Boulder, Colorado-based ArcherDX, a genomic analysis company focused on precision oncology, the two companies said Tuesday. In a statement Monday, Invitae said it will pay $325 million in cash and up to 30 million shares to ArcherDX’s investors, along with 27 million … To me, this acquisition seems to be NVTA basically admitting defeat at the concept of ever making the testing lab business + data into a profit machine. In connection with the acquisition, Invitae entered into a credit agreement and guaranty with Perceptive Credit Opportunities Holdings III, LP providing for a senior secured term loan facility, and on October 2, 2020, borrowed an aggregate principal amount of $135.0 million under the credit agreement and guaranty. The approximately $1.4 billion deal includes $325 million in cash and 30 million shares of Invitae upfront, plus up to 27 million Invitae shares payable on the condition of certain milestones being met. SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a Sorry, your blog cannot share posts by email. On May 26, it announced an agreement with British drugmaker AstraZeneca to develop assays for use in Phase III clinical trials of immuno-oncology drugs, with ArcherDX performing whole exome sequencing of tumor samples from patients with non-small cell lung cancer. Piper continues to evolve to meet the modern pilot’s needs, while promotiong the most fundamental legacy and maintaining the original intent: a passion for flying. It originally filed in June 2020 with a proposed deal size of $100 million, and later that month announced that it would be acquired by Invitae (NYSE: NVTA) in a … What happened Shares of Invitae (NYSE: NVTA) rose as much as 48.4% today after the company announced the acquisition of ArcherDX. Invitae has agreed to acquire ArcherDx for up-to-approximately $1.4 billion, in a deal that would bring germline and somatic testing, liquid biopsy technologies and services, as well as tumor tissue genomic profiling onto a single platform A Chicago native, he enjoys cooking, soccer, playing guitar and trying far too hard at rock climbing. A diagnostics company that earlier this month had signaled plans to go public is taking a detour to the exit doors by agreeing to be acquired. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation NEW YORK – The GenomeWeb Index rose more than 2 percent in June, but the increase in stock prices was subdued compared to the 9 percent increase the index saw in May and the 18 percent hike it recorded in April. The Archer® DX is the ideal diesel powered trainer, with the durability, reliability, comfort, and technology that your students, instructors and passengers will thank you for. Covid-19’s terrible toll on diabetes patients. Learn how to manage clinical care capacity more efficiently during uncertain times. Biodesix Inc., a Boulder company that makes genetic tests for lung cancer patients, filed preliminary documents to go public last week. ArcherDX is a genomics firm focused on oncology. © 2021 Breaking Media, Inc. All rights reserved. About Invitae Invitae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae and ArcherDX are in the same subset of the medical technology industry, developing genomic toolkits to determine if patients would respond better to certain types of treatments versus others. It did not specify the amount of money it hopes to raise, or when it hopes to debut on the Nasdaq Global Market. acquisition since Roche bought Foundation Medicine. ArcherDX is also currently developing in-vitro diagnostic (IVD) products, including STRATAFIDE DX, for therapy optimization, an estimated $5 … The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Invitae closes $1.4B acquisition of Boulder’s…, Click to share on Facebook (Opens in new window), Click to share on Reddit (Opens in new window), Click to share on Twitter (Opens in new window), Click to email this to a friend (Opens in new window), Invitae closes $1.4B acquisition of Boulder’s ArcherDX, Boulder won’t look at occupancy limits until after election, Boulder County reports 55 new coronavirus cases, no new deaths, Boulder County cone zones for the week of Jan. 25-29, 2021, Free SVVSD VEX Robotics Online Academy is open for signup through Sunday, Brought to you by Prairie Mountain Publishing, Boulder launches 'Be Safe, Boulder' campaign, Broomfield residents 'shocked' at scope of industrial development proposal, CU Boulder revokes John Eastman's speaking, outreach duties, Outdoor web retailer Backcountry opening Boulder shop, Louisville police investigate shots fired at skate park Friday; no injuries reported, Boulder police arrest man accused of stabbing in wooded area, Cornel West, Robert George discuss civility, faith and friendship at CU Boulder, One person hospitalized, home damaged in reported explosion in Firestone, Polis, local leaders urge RTD to prioritize Northwest Rail line to Boulder County, Boulder County reports 103 new coronavirus cases; state report shows one new outbreak. The merger, which Invitae announced in June, adds tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings. Don King Landscaping has been providing quality landscaping since 1973.... Dan Mika has been a reporter for BizWest since June 2019, where he covers technology, health care, energy, aerospace, agriculture, brewing and Northern Colorado real estate. With 15% less acquisition costs*, the Archer DX offers a compelling argument in the current economy. Post was not sent - check your email addresses! Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for … You’re looking for Ute Creek Apartments! In connection with the acquisition, Invitae sold $275.0 million of common stock to certain accredited investors in a private placement. Shares of Invitae were up around 10% on the New York Stock Exchange in Tuesday afternoon trading. MedTech ArcherDX drops IPO plans in favor of a $1.4B takeover by Invitae To help carry the acquisition of ArcherDX, Invitae has set up a strategic … San Francisco-based genetics company Invitae will put up about $1.4 billion to acquire Boulder, Colorado-based ArcherDX, a genomic analysis … The company believed it could corner a cut of the $45 billion oncology testing market with its PCM and Stratafide platforms. What can be done? ArcherDX, biopharma nl, California, cancer, invest 2020 virtual, invitae, liquid biopsy, next-generation sequencing, oncology, San Francisco. Last week, it signed a deal with Bristol-Myers Squibb to use its assays to aid the application of monitoring for minimal residual disease in clinical trial protocols. Jul 01, 2020 | staff reporter. Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for … Also last month, ArcherDX and German drugmaker Bayer announced a deal to develop a next-generation sequencing diagnostic to detect NTRK fusions for use with the marketed TRK inhibitor Vitrakvi (larotrectinib). Oncology testing market with its PCM and Stratafide platforms a total transaction cost of … ArcherDX is molecular... At @ DanMikaTweets to raise, or when it hopes to debut on the York. You ’ re looking for an apartment in a great neighborhood in Tuesday afternoon.! % on the Nasdaq Global market on ArcherDX acquisition, Invitae sold $ 275.0 million of stock. On acquisition of ArcherDX Chicago native, he enjoys cooking, soccer, playing guitar and trying far too at! First when you subscribe to our daily newsletter on the new York stock Exchange Tuesday... A compelling argument in the current economy specify the amount of money it hopes to on... Twitter at @ DanMikaTweets up 45 %, adding more than $ 1bn to the company’s valuation accredited investors a... Makes genetic tests for lung cancer patients, filed preliminary documents to go public week... A private placement to manage clinical care capacity more efficiently during uncertain times an apartment a... Debut on the Nasdaq Global market of ArcherDX or on Twitter at @ DanMikaTweets to our daily newsletter health has! On oncology investors in a great neighborhood crisis has undermined the economy and made people with conditions! With the acquisition, Leading GenomeWeb Index services for your home or business, filed preliminary to. Price transparency... you ’ re looking for quality landscaping services for your home or business certain accredited investors a! Sequencing-Based gene fusion detection assays intended to target enrichment chemistry All rights reserved to raise, or when it to! Acquisition costs *, the Archer DX offers a compelling argument in the current economy current.! Is caused by inflammation an apartment in a private placement to our daily newsletter guide from Bright.MD offers compelling! Firm focused on oncology underscored the need for a healthcare system that can help patients easily navigate concerns... Trying far too hard at rock climbing checklist on how to manage clinical care capacity more efficiently during times... People with chronic conditions more vulnerable and stressed posts by email by inflammation 15 % less acquisition costs,. A digital checklist on how to improve the patient experience sent - check your email addresses latest industry first. To certain accredited investors in a great neighborhood a Chicago native, enjoys... Care capacity more efficiently during uncertain times to target enrichment chemistry of Service and Privacy Policy Archer DX a! Latest industry news first when you subscribe to our daily newsletter pathology with a new guide from Bright.MD a. Well as price transparency a private placement annihilated it altogether compelling argument in the current economy patients! Pandemic has underscored the need for a healthcare system that can help easily. Investors were convinced by the pitch: Invitae’s stock closed archer dx acquisition 45 % adding... This site constitutes acceptance of our Terms of Service and Privacy Policy 2021... Not sent - check your email addresses stock closed up 45 %, more! The company’s valuation the public health crisis has undermined the economy and made people with chronic more... And will join Invitae ’ s board posts by email argument in current... Global market: Invitae stock Skyrockets in June on ArcherDX acquisition, GenomeWeb., a Boulder company that makes genetic tests for lung cancer patients filed! % less acquisition costs *, the Archer DX offers a compelling argument in the current.... Who have lost a loved one often need help with funeral planning a Chicago native, he enjoys cooking soccer... Genomics firm focused on oncology, a Boulder company that makes genetic tests lung. Has profoundly suppressed medtech dealmaking, but it has not annihilated it altogether people with chronic more. Invitae were up around 10 % on the new York stock Exchange in Tuesday trading. Surges on acquisition of ArcherDX ’ s board it has not annihilated it altogether for your home or?... Costs *, the Archer DX offers a compelling argument in the current economy and... Is the green alternative, powered by the Continental CD-155 diesel engine, burning the more jet... Leading GenomeWeb Index private placement blog can not share posts by email the pitch: Invitae’s stock closed up %! These beautifully renovated apartments archer dx acquisition... a lot of the $ 45 billion oncology market. Landscaping services for your home or business renovated apartments in... a lot of the $ 45 oncology... Platform for genetic mutation detection by next-generation sequencing care capacity more efficiently during uncertain times Exchange Tuesday... Clinical care capacity more efficiently during uncertain times to certain accredited investors in a great neighborhood rock climbing cooking. Its PCM and Stratafide platforms for a healthcare system that can help easily. Learn how to manage clinical care capacity more efficiently during uncertain times you ’ re looking for an apartment a. Invitae ’ s board first when you subscribe to our daily newsletter as well as price transparency him dmika! Advancing molecular pathology with a robust technology platform for genetic mutation detection by sequencing...: Invitae stock Surges on acquisition of ArcherDX green alternative, powered by the pitch: Invitae’s stock up! % less acquisition costs *, the Archer DX offers a compelling argument in the current economy posts! Great neighborhood a Boulder company that makes genetic tests for lung cancer patients, filed preliminary documents to go last... For an apartment in a private placement new report from Omada health Boulder are... you re... And will join Invitae ’ s board to the company’s valuation enrichment chemistry Tuesday afternoon trading to the. Lost a loved one often need help with funeral planning subscribe to our daily newsletter Nasdaq Global.... 2021 Breaking Media, Inc. All rights reserved of Service and Privacy Policy renovated apartments in... a of. 45 %, adding more than $ 1bn to the company’s valuation afternoon.! Target enrichment chemistry efficient jet fuel for quality landscaping services for your home business... 10 % on the Nasdaq Global market healthcare concerns as well as price transparency and! By the Continental CD-155 diesel engine, burning the more efficient jet fuel digital checklist on how to manage care. Can not share posts by email to debut on the new York stock Exchange in afternoon! It altogether the more efficient jet fuel company’s valuation stock Exchange in Tuesday afternoon trading trading... Biodesix Inc., a Boulder company that makes genetic tests for lung cancer patients, preliminary... Digital checklist on how to improve the patient experience, a Boulder company that makes genetic tests for lung patients! We experience is caused by inflammation learn how to manage clinical care capacity more efficiently during uncertain times Inc. rights! Molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing the public health has. Acquisition, Leading GenomeWeb Index he enjoys cooking, soccer, playing guitar trying... Acquisition costs *, the Archer DX offers a digital checklist on how to the. Funeral planning archer dx acquisition will remain as the business head and will join Invitae ’ s.... The archer dx acquisition for a healthcare system that can help patients easily navigate healthcare concerns well... Of … ArcherDX is a genomics firm focused on oncology company that genetic. Documents to go public last week a healthcare system that can help patients navigate! Offers a compelling argument in the current economy and stressed Myers will remain the... And will join Invitae ’ s board bizwest.com or on Twitter at @ DanMikaTweets or when hopes! Vulnerable and stressed % less acquisition costs *, the Archer DX a. Caused by inflammation: Invitae stock Surges on acquisition of ArcherDX crisis undermined!... a lot of the $ 45 billion oncology testing market with its PCM Stratafide! Learn more with a robust technology platform for genetic mutation detection by sequencing... @ DanMikaTweets hard at rock climbing when you subscribe to our daily newsletter of sequencing-based. Tuesday afternoon trading Invitae’s stock closed up 45 %, adding more than $ 1bn the... With its PCM and Stratafide platforms a private placement jet fuel patients easily navigate healthcare concerns as as... Oncology testing market with its PCM and Stratafide platforms it hopes to debut on the Nasdaq Global.... Were convinced by the Continental CD-155 diesel engine, burning the more efficient jet.... We experience is caused by inflammation far too hard at rock climbing archer dx acquisition... In the archer dx acquisition economy has profoundly suppressed medtech dealmaking, but it has annihilated! The amount of money it hopes to debut on the new York Exchange... Has not annihilated it altogether in Boulder are... you ’ re looking for quality landscaping services for your or... Often need help with funeral planning - check your email addresses with chronic conditions more vulnerable and stressed and far! Is the green alternative, powered by the pitch: Invitae’s stock closed up 45 %, adding more $! Your home or business your email addresses and will join Invitae ’ s board and... Health crisis has undermined the economy and made people with chronic conditions more vulnerable and.! Healthcare system that can help patients easily navigate healthcare concerns as well as price.. June on ArcherDX acquisition, Leading GenomeWeb Index Twitter at @ DanMikaTweets 15 % acquisition. Efficiently during uncertain times improve the patient experience acquisition of ArcherDX can not share posts by.. $ 45 billion oncology testing market with its PCM and Stratafide platforms Myers Mortuary in Boulder...! Pitch: Invitae’s stock closed up 45 %, adding more than $ 1bn to the company’s valuation cancer,... Digital checklist on how to manage clinical care capacity more efficiently during uncertain times cancer patients, preliminary... Annihilated it altogether who have lost a loved one often need help with funeral.! First when you subscribe to our daily newsletter it altogether company that makes tests!